<DOC>
	<DOCNO>NCT01021800</DOCNO>
	<brief_summary>Interventional study modulation immune response patient pancreatic tubular adenocarcinoma resection gemcitabine treatment . When include , patient pre-treated moderate dos cyclophosphamide . Then infusion allogeneic mononuclear cell give .</brief_summary>
	<brief_title>Modulation Immune Response Patients With Pancreatic Tubular Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>ECOG performance status 02 time inclusion Following R0 R1 pancreatic tubular adenocarcinoma resection adjuvant gemcitabine treatment Pregnancy Less 3 mths expect survival Serious comorbidity Age 70 yr</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Pancreatic tubular adenocarcinoma adjuvant set</keyword>
</DOC>